Caisse DE Depot ET Placement DU Quebec Acquires New Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Caisse DE Depot ET Placement DU Quebec purchased a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 19,000 shares of the biotechnology company's stock, valued at approximately $2,310,000.

A number of other institutional investors also recently modified their holdings of the business. Manchester Capital Management LLC raised its position in Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 156 shares during the last quarter. Newbridge Financial Services Group Inc. acquired a new stake in Sarepta Therapeutics during the 4th quarter worth about $36,000. Steward Partners Investment Advisory LLC grew its stake in Sarepta Therapeutics by 164.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock worth $38,000 after purchasing an additional 194 shares during the period. Finally, Smartleaf Asset Management LLC increased its stake in shares of Sarepta Therapeutics by 95.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company's stock valued at $54,000 after acquiring an additional 216 shares in the last quarter. Institutional investors own 86.68% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on SRPT shares. HC Wainwright cut their price target on Sarepta Therapeutics from $75.00 to $40.00 and set a "neutral" rating on the stock in a report on Wednesday. Oppenheimer decreased their price objective on shares of Sarepta Therapeutics from $184.00 to $123.00 and set an "outperform" rating for the company in a research note on Wednesday. Deutsche Bank Aktiengesellschaft cut their price target on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating on the stock in a report on Wednesday, March 19th. Guggenheim reduced their price objective on Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating for the company in a report on Wednesday. Finally, Piper Sandler lowered their price target on shares of Sarepta Therapeutics from $110.00 to $70.00 and set an "overweight" rating on the stock in a research report on Wednesday. Six equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $137.09.

Sarepta Therapeutics Price Performance

SRPT traded down $10.03 during midday trading on Wednesday, hitting $36.72. 20,719,614 shares of the company traded hands, compared to its average volume of 1,565,504. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 52-week low of $36.49 and a 52-week high of $173.25. The company has a market capitalization of $3.61 billion, a price-to-earnings ratio of 29.38 and a beta of 0.85. The business has a 50 day simple moving average of $69.47 and a two-hundred day simple moving average of $102.12.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The business had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. During the same quarter in the prior year, the company posted $0.73 earnings per share. The company's revenue was up 80.2% on a year-over-year basis. On average, equities analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the firm's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the transaction, the director now owns 27,812 shares of the company's stock, valued at approximately $2,771,187.68. This trade represents a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 7.70% of the stock is owned by corporate insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.